Zhejiang Jolly Pharmaceutical acquires trace elements injection assets for 356m yuan

Zhejiang Jolly Pharmaceutical Co., Ltd. has agreed to acquire the "Multiple Trace Elements Injection Asset Group" from Tibet Future Biomedical Co., Ltd. and its subsidiaries for a total of 356 million yuan (including tax). The asset group includes approved products like "Multiple Trace Elements Injection (I)" and "(II)," along with "Multiple Trace Elements Injection (III)" in development. This encompasses R&D, production technology, marketing licenses, trademarks, patents, and associated personnel. The acquisition aims to optimize Zhejiang Jolly Pharmaceutical's product structure and expand its presence in disease treatment, particularly in women's, children's, and elderly healthcare.

The transaction was approved during the company's board meeting on December 12, 2025. The board also approved an adjustment to the company's organizational structure to enhance corporate governance and operational efficiency. The acquisition leverages Zhejiang Jolly Pharmaceutical's marketing strengths and Tibet Future Biomedical's established market presence to achieve synergistic growth and deeper market penetration.

The acquired asset group demonstrates strong profitability, with a net profit of 45,789,200 yuan from January to September 2025. While the acquisition is expected to improve the company's profitability and market competitiveness, the transfer of drug marketing authorizations and potential changes in centralized procurement selections present regulatory and market risks.